EIGHTEENTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of June 5, 2014, among ALERE INC., a Delaware corporation (the “Issuer”), each of the Guarantors under the Indenture referred to below (the “Guarantors”), and U.S. BANK...Eighteenth Supplemental Indenture • March 5th, 2015 • Alere Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS the Issuer has heretofore executed and delivered to the Trustee an Indenture dated as of May 12, 2009, as amended, supplemented and modified by a Sixteenth Supplemental Indenture dated as of May 24, 2013 (as so amended, supplemented and modified, and as further amended, supplemented or modified to date, the “Indenture”), by and among the Issuer, the Guarantors and the Trustee, providing for the issuance of 6.500% Senior Subordinated Notes due 2020 (the “Notes”);
SIXTH AMENDMENT TO CREDIT AGREEMENTCredit Agreement • March 5th, 2015 • Alere Inc. • In vitro & in vivo diagnostic substances • New York
THIS SIXTH AMENDMENT TO CREDIT AGREEMENT (this “Sixth Amendment”), dated as of December 1, 2014, among ALERE INC., a Delaware corporation (the “Borrower”), each of the Guarantors (as defined in the Credit Agreement referred to below) party hereto, the Lenders (as defined in the Credit Agreement referred to below) party hereto and GENERAL ELECTRIC CAPITAL CORPORATION, as administrative agent (in such capacity, the “Administrative Agent”) for the Lenders, is made with reference to that certain Credit Agreement, dated as of June 30, 2011 (as amended, modified or supplemented through, but not including, the date hereof, the “Credit Agreement”), by and among the Borrower, the Lenders, the Administrative Agent and the other parties thereto. Unless otherwise indicated, all capitalized terms used herein and not otherwise defined herein shall have the respective meanings ascribed to such terms in the Credit Agreement.
TWENTIETH SUPPLEMENTAL INDENTURESupplemental Indenture • March 5th, 2015 • Alere Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS the Issuer has heretofore executed and delivered to the Trustee an Indenture dated as of May 12, 2009, as amended, supplemented and modified by a Sixteenth Supplemental Indenture dated as of May 24, 2013, and an Eighteenth Supplemental Indenture dated as of June 5, 2014 (as so amended, supplemented and modified, and as further amended, supplemented or modified to date, the “Indenture”), by and among the Issuer, the Existing Guarantors and the Trustee, providing for the issuance of 6.50% Senior Subordinated Notes due 2020 (the “Notes”);
NINETEENTH SUPPLEMENTAL INDENTURESupplemental Indenture • March 5th, 2015 • Alere Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS the Issuer has heretofore executed and delivered an Indenture dated as of May 12, 2009, as amended, supplemented and modified by a Ninth Supplemental Indenture dated as of September 21, 2010, an Eleventh Supplemental Indenture dated as of June 16, 2011, a Thirteenth Supplemental Indenture dated as of June 16, 2011, a Fifteenth Supplemental Indenture dated as of April 3, 2013, and a Seventeenth Supplemental Indenture dated as of June 5, 2014 (as so amended, supplemented or modified, and as further amended, supplemented or modified to date, the “Indenture”), by and among the Issuer, the Existing Guarantors and the Trustee, providing for the issuance of 8.625% Senior Subordinated Notes due 2018 (the “Notes”);
